U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta - Reuters

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta  Reuters

The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta.



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked